Christina Callihan
Psychiatric/Mental Health · Richmond, KYNPI 1164096483
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,444 of the $47,993 with a category attached, or 73.9%. Axsome Therapeutics, Inc. accounts for 74.0% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $46,196, more than ten times the $204 reported in 2021. Among psychiatric/mental health clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 306 payments — averaging $156.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$36K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$8K
- AbbVie$2K
- E.r. Squibb & Sons, L.L.C.$1K
- Vanda Pharmaceuticals Inc.$738
- Alkermes, Inc.$325
- plus $819 from 16 others
What the payments were for
- Consulting fees$2,8736%
- Speaking & faculty fees$35,44474%
- Travel & lodging$4,3759%
- Food & beverage$5,30111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 64 | $35,508 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 76 | $7,681 |
| AbbVie | 44 | $1,555 |
| E.r. Squibb & Sons, L.L.C. | 20 | $1,366 |
| Vanda Pharmaceuticals Inc. | 39 | $738 |
| Alkermes, Inc. | 19 | $325 |
| Otsuka America Pharmaceutical, Inc. | 13 | $253 |
| Almatica Pharma LLC | 6 | $152 |
| Indivior Inc. | 5 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $51 |
| Noven Therapeutics, LLC | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| Eisai Inc. | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Biohaven Pharmaceuticals, Inc. | 2 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| Lundbeck LLC | 1 | $20 |
| SK Life Science, Inc. | 1 | $17 |
| Merck | 1 | $15 |
| Orexo US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$47,993 in reported general payments places this provider in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 87 | $122,111 |
| CaplytaLumateperone Tosylate | 44 | $84,699 |
| RexultiBrexpiprazole | 44 | $63,587 |
| TrintellixVortioxetine Hydrobromide | 109 | $53,832 |
| Invega SustennaPaliperidone Palmitate | 12 | $32,434 |
| Lurasidone Hcl | 42 | $10,595 |
| Aripiprazole | 65 | $8,117 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,129 |
| Clonazepam | 417 | $1,369 |
| Vilazodone Hcl | 18 | $1,255 |
| Quetiapine Fumarate | 101 | $911 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 31 | $898 |
| Olanzapine | 54 | $785 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 16 | $717 |
| Duloxetine Hcl | 59 | $673 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,555 | $122,11187 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $7,681 | $84,69944 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $253 | $63,58744 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $51 | $57,961120 claims |
| Johnson & JohnsonInvega Sustenna | $22 | $32,43412 claims |
| Lilly USA, LLCOlanzapine | $21 | $78554 claims |
| Almatica Pharma LLCSertraline Hcl | $152 | $31783 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Richmond
- Tina Shelton-CoomerRichmond$28K
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Denise de AngelisLouisville$384K
- Jennifer SampangCrestview Hills$322K
- Jeremy FisherSouth Shore$197K
- Jessica EstesLewisport$175K
- Christopher MulloneyNancy$95K
- Davika MattoxMorehead$79K
- Molly LutzCrestview Hills$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.